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Abstract
Background
The landscape of Human Immunodeficiency Virus (HIV) epidemic control is shifting with the
United Nations Programme on HIV/AIDS (UNAIDS) 90-90-90 benchmarks for epidemic
control. Community-based Antiretroviral Therapy (CART) models have improved treatment
uptake and demonstrated good clinical outcomes. We assessed the feasibility of integrating
community pharmacy as a task shift structure for differentiated community ART in Abuja-
Nigeria.
Methods
Stable patients on first line ART regimens from public health facilities were referred to com-
munity pharmacies in different locations within the Federal Capital Territory, Abuja for pre-
scription refills and treatment maintenance. Bio-demographic and clinical data were
collected from February 25, 2016 to May 31st, 2017 and descriptive statistics analysis
applied. The outcomes of measure were prescription refill and patient retention in care at
the community pharmacy.
Results
Almost 10% of stable patients on treatment were successfully devolved from eight health
facilities to ten community pharmacies. Median age of the participants was 35 years [inter-
quartile range (IQR); 30, 41] with married women in the majority. Prescription refill was
100% and almost all the participants (99.3%) were retained in care after they were devolved
to the community pharmacies. Only one participant was lost-to-follow-up as a result of
death.
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Conclusion
Excellent prescription refill and high retention in care with very low loss-to-follow-up were
associated with the community pharmacy model. The use of community pharmacy for com-
munity ART is feasible in Nigeria. We recommend the scale up of the model in all the 36
states of Nigeria.
Introduction
The success of anti-retroviral therapy (ART) in reducing the mortality, morbidity and trans-
mission of Human Immunodeficiency Virus (HIV) has provided hope for ending the HIV epi-
demic in the absence of a preventive vaccine [1–4]. The World Health Organization (WHO) is
promoting the use of community based ART in a global strategy to end HIV/AIDS by 2030.
The community based ART approach is overwhelmingly supported because it seems to be the
only viable strategy for delivering HIV treatment services closer to the people and improving
ART uptake, retention in care and decongesting overburdened public health facilities [5]. In
sub-Saharan Africa, the community based ART is being promoted as the key for treating the
over 20 million people living with the HIV/AIDS (PLWHA) [6]. The last decade particularly
witnessed a progressive shift from hospital-based ART to primary health centers and more
recently to the community [7–10]. In effect, the community based approach to treating HIV/
IDS has always been in the background but was not well publicized.
Different models of community ART are being implemented in sub-Sahara Africa but there
is limited data on the involvement of community pharmacy in the delivery of ART within the
community [11–14]. In the western countries however, several studies have documented the
different roles community pharmacies can play in the treatment of HIV/AIDS [15–19].
Community pharmacies in Nigeria are registered private pharmaceutical premises licensed
by the Pharmacists Council of Nigeria—the body responsible for the education of pharmacists
and pharmacy practice in Nigeria. In 2014, there were 530 registered community pharmacies
in the Federal Capital Territory (personal communication with Pharmacists Council of Nige-
ria). The community pharmacies are different from the Patent Medicine Vendors (PMV) in
several ways. PMVs are registered to dispense over-the-counter drugs but the community
pharmacies dispense prescription drugs and are managed by superintendent pharmacists
referred here as community pharmacists (CPs). Annual license to “import, export, prepare,
dispense, and distribute drugs and poisons” are issued to the CPs by the Pharmacists Council
of Nigeria [20], while PMVs are issued with the PMV license.
Nigeria had the second highest burden of HIV/AIDS in the world with an estimated
3,391,546 PLWHA in 2014 [4]. Although new infections have declined from an estimated
316,733 in 2003 to 239,155 in 2014, a total of 174,253 people died from AIDS related causes in
2014 [4]. The estimated number of persons in need of ART using the eligibility criteria of CD4
of350 cells/mm3 in 2014 was 1,665,403 (1,454,565 adults and 210,838 children) but only
748, 846 adults and children, representing 44.3% received prescription for ART in 2014 [4].
This implies that the verse majority of Nigerians living with the HIV are yet to receive ART.
The “Test and Start” treatment strategy currently implemented in high burden priority local
government areas will require (upon scale up) that all the estimated 3.5 million PLWHA in
Nigeria to receive prescription for ART. Given that the limited health facilities in the country
lack the capacity to absorb the large number of patients waiting for ART, the United States
Emergency Plan for AIDS Relief (PEPFAR) program in Nigeria is planning to increase uptake
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of ART using the differentiated care model, which include the community pharmacy ART
programme [21].
This paper presents the outcome of a pilot use of community pharmacies for ART delivery
to assess the feasibility of implementation in Nigeria. There were two main objectives: (a).
determine the rate of prescription refill and (b) retention in care/loss-to-follow-up over a
period of 12 months.
Methods
Ethics
Ethical approval was given by the National Health Research Ethics Committee of Nigeria
under the title: “Engaging indigenous organization to sustain and enhance clinical services for
the prevention, care and treatment of HIV/AIDS in the Federal Republic of Nigeria under the
President’s Emergency Plan for AIDS Relief (PEPFAR)”; Number: NHREC/01/01/2007; dated
August 12, 2016. The Institute of Human Virology Nigeria, headed by Dr. Patrick Dakum,
obtained this ethical clearance for all the studies conducted under the institute.
Setting
The Federal Capital Territory houses Abuja, the capital city of Nigeria. It has a population of
less than two million people and most of the urban dwellers are civil servants, while the rural
areas are inhabited by farmers. The territory has six area councils: Bwari, Abuja Municipal,
Abaji, Kuje, Gwagwalada and Kwali. This pilot study was conducted in the Abuja Municipal
and Bwari Area Councils. These two councils are designated by the Government of Nigeria as
HIV service priority Local Government Areas because of their high HIV burden. The HIV
prevalence in the Abuja Municipal Area Council is estimated at 6.3% and 10.2% in the Bwari
Area Council [4].
Selection of health facilities and community pharmacies
We selected community pharmacies based on their expression of interest to participate and
meeting the eligibility criteria. Prior to the selection, we approached community pharmacy
owners at their professional association meetings and informed them of the study. Those who
indicated interest and met the eligibility criteria of having a secured place for patient counsel-
ling, a temperature-regulated drug store, an efficient record keeping system and a superinten-
dent pharmacist were requested to complete an evaluation form and provide a written
informed consent. Priority was given to pharmacies located in areas that are readily accessible.
Eight busy health facilities were purposively selected for patient referrals. In selecting the
health facilities, we considered from a list of health facilities supported by the Institute of
Human Virology Nigeria through the United States President Emergency Plan for AIDS Relief
project. The locations, HIV care services and willingness to provide written informed consent
to participate in the pilot referral program were prioritized.
Training of medical doctors and pharmacists
The health care providers including medical doctors and pharmacists from the selected health
facilities and community pharmacies received trainings for the implementation of this pilot
project. The training focused on patient recruitment, referrals, ART and pharmacovigilance
and documentation. We also developed protocols for the referring facilities and community
pharmacies and provided tools like laptop computers and all the official documents for record
documentation. A memorandum of understanding (MoU) was also developed, which the
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pharmacists signed with the IHVN. The MoU is an official contract that describes the scope
of work and the financial stipend the community pharmacies were paid to cover the services
they provided to the participants. Community pharmacies were not permitted to charge a ser-
vice-fee or charge for the drugs, i.e., patients received drugs and services free of all financial
charges.
Implementation
Referral system. The selected public health facilities (hospitals) and the community phar-
macies were consecutively engaged in the program at different times for logistical reasons.
Patient inclusion criteria into the community ART were:
1. Patient stability, defined by duration of facility-based ART of 6months with successful
suppression of viral load below detection level (20 copies/ml);
2. ART regimen—only patients on first line ART regimens (Tenofovir 300mg/Lamivudine
300mg/Efavirenz600mg or Zidovudine300mg/Lamivudine150mg/Nevirapine200mg) were
considered for referral to the community pharmacies
3. Willingness to participate, expressed through written consent.
Patients previously lost to follow up or had unstructured treatment interruptions were
excluded from enrollment into the pilot. Pediatric and patients with co-morbidities were also
excluded from enrollment. Eligible patients were given the choice to continue to receive ART
from a list of ten community pharmacies located in different places within the Abuja Munici-
pal and Bwari Area Councils.
Before the referrals, patients were informed about the benefits of community ART by
trained health facility staff. Some of the benefits enumerated to the patients were lower trans-
port cost to collect medications and better access to drug refill. They were also informed of the
following risks: disclosure of HIV status from accidental breach of confidentiality and missing
hospital visit if they forget to visit the health facility for viral load monitoring on the due date.
The community pharmacies were informed of patients’ referral by the health facilities
ahead of time. Referral documents were prepared by the health facilities; patients took the
referral document and ART prescription form (Pharmacy Order Form) to their preferred
community pharmacies. The Pharmacy order form specifies the ART regimen the patient was
treated with prior to the referral; the CPs dispenses this original regimen in bimonthly pre-
scription refill visits. In some health facilities, patients were referred with about two to three
months’ worth of drugs, while in other health facilities; drugs were not given at the time of
referral. For patients who were referred with drugs, visit to the community pharmacies for pre-
scription refill was delayed until the drugs were almost completely exhausted. For the patients
who were referred without drugs, visit to the community pharmacies to refill prescription was
done almost immediately.
ART refills. ART prescriptions written by physicians were dispensed by the CPs who also
provided counseling and monitored adherence and adverse drug reactions in addition to drug
logistic and data management services. Prescriptions were generally refilled bimonthly but in
special circumstances (like when a patient has to travel away from his home for many months),
a three month worth of medications could be dispensed. Only adult first line regimens and
Cotrimoxazole prophylaxes are offered but there is plan to expand the regimen mix to include
second line regimens.
During the pilot phase, drug dispensing took place in secured locations to protect patients’
privacy and confidentiality while counseling. The CPs collected routine care information and
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captured the data in patient’s treatment card and program computer software called “Intelli-
gent Dispensing of Antiretroviral Treatment” (iDART). The next refill appointment date was
given to the patient at the end of each refill activity. Patients observed to be ill or in need of
clinical care or those with adverse drug reaction were referred back to the health facilities that
referred them to the community pharmacy for evaluation and treatment. Patients remained
permanently linked to the health facilities through such referrals and routine care assessment
like the viral load tests. The CPs were responsible for ensuring patients returned to the hospi-
tals for routine care assessment at the due date. They also provided leadership and manage-
ment services in maintaining cordial relationships with patients and other health care
providers. Studies have shown that optimal adherence and retention in care are driven by
healthcare providers’ attitude to the patients in addition to factors like counselling, peer sup-
port group, reduced pill burden and short travel distance to health facility [22–26].
Pharmacovigilance services. Pharmacovigilance service was included in our model
because several studies in the United States of America, Europe and Brazil have reported car-
dio-metabolic disorders associated with the use of antiretroviral drugs [27–30]. These disor-
ders have also been reported in sub-Sahara Africa among people treated for HIV [31–36].
Monitoring and reporting of ADRs was therefore considered an important activity for improv-
ing the quality of care for the community pharmacy ART model.
Data collection
Program data for this pilot project were accessed through lap top computers provided to the
participating community pharmacies and referring hospitals. These data were transferred
online to a central server on weekly basis. S1 Table. Access to the database is protected by two
level passwords at the initial log on and for the database.
De-identified data were abstracted and organized into cell counts in which descriptive val-
ues were provided along with frequencies and proportions. We collected data from February
25, 2016 to May 31st, 2017 and applied descriptive statistics to report our findings.
Results
A total of 295 participants were consecutively referred from eight public health facilities to ten
community pharmacies within the 12 months review period. Median age was 35 years (30; 41);
married women constituted 72% and the “self-employed” (e.g., business men, artisans) partici-
pants accounted for 42.8%. Baseline median viral load was 19 copies/mL and CD4 counts, 460
cells/mL (Table 1).
Table 2 presents the outcome of the pilot within the review period. Almost 10% (295) of the
people treated for HIV/AIDS at the study centers were devolved to community pharmacies.
The rate of prescription refill was excellent (100%)–on the average, participants’ refilled pre-
scriptions bimonthly four times, which is equivalent to eight months of continuous therapy in
the community pharmacies. Retention in care was very high (99.3%) and only one participant
was lost-to-follow -up.
Discussion
This Pilot Community-based ART delivery Model has demonstrated the feasibility of using
the community pharmacies in Nigeria for community HIV management. Previous studies
reported the successes of other community based ART models [7,9–11], however, some of
these models are not based on sustainable structures within the community. Our model is
based on the community pharmacies, which are existing structures the communities patronize
for health care services.
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There are three important findings that our model has demonstrated. Firstly, we showed
that patients referral from the health care facilities to the community pharmacies is feasible
and sustainable. Secondly, excellent prescription refill and retention in care—significant vari-
ables for ending HIV, can be achieved and thirdly, we witnessed a gradual decongestion of
health facilities through the referral activities. The decongestion has the advantage of creating
more space for new patients to be recruited and at the same time, freeing health care providers’
time for the treatment of critical and complicated co-morbidities. Our findings support what
other studies have reported on the potential of community based ART to improve retention in
care and decongest over-crowded public hospitals [7,10,11].
A major strength of our model is its foundation on the community pharmacy, recognized
as the first point of call for patients seeking health service in the community. But there are sev-
eral limitations that may constrain the full operationalization of the model. The community
pharmacies do not exist in some remote rural communities where only the Patent Medicine
Vendors operate. However, most of the people living with HIV/AIDS live in the sub-urban
areas [37] where the community pharmacies can be found. Another significant limitation of
the model is the overwhelming support it enjoyed; the community pharmacies would probably
not have performed as they did if they were not well resourced. However, despite these limita-
tions, the community pharmacy model can become an overarching comprehensive HIV care
Table 2. Overall outcome of the pilot study within the review period.
Assessment variable Number (%); Median [IQR]
Participants referred to community pharmacies 295 (8.3%)
Median prescription refill* 4 [2; 5]
Prescription refill rate 100%
Median Follow up period (months) 8 [4;10)
Retention in care (in the community pharmacy) 287 (99.3%
Lost-to-follow-up 1 (0.35%)
Death 1 (0.35%)
Note *: The median prescription refill is a measure of the number of times participants’ refilled prescriptions.
https://doi.org/10.1371/journal.pone.0190286.t002
Table 1. Baseline demographic and clinical characteristics of the participants.
Sociodemographic characteristics Number (%); Median [IQR*]
Age (years) 35 [30; 41]
Gender
Women
Men
208 (71.0)
85 (29.0)
Marital Status
Married
Single
Widow
200 (72.7)
68 (24.7)
7 (2.6)
Employment
Self Employed
Employed
Unemployed
119 (42.8)
93 (33.5)
66 (23.7)
Clinical characteristics
Viral load (Copies/mL)
CD4 count(Cells/mL)
19 [19; 32]
460 [277; 648]
*IQR = interquartile range
https://doi.org/10.1371/journal.pone.0190286.t001
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model that would play a central part in the overall response to the HIV epidemic in Nigeria, if
rolled out in every part of the country. The model can also promote the realization of the “treat
all” global strategy for ending HIV, considering that most of the people living with HIV/AIDS
are in the communities where the model can be operated.
Public health significance of the model
In Africa, qualified clinical staffs to provide optimal care, especially ART is lacking [38]. In
rural Africa, the low geographical density of health structures creates a heavy burden on
patients who may have to travel long distances to seek care. A study conducted in North-Cen-
tral Nigeria by Avong et al [39] found that patients paid a median of USD5:00 (equivalent to
2,000 Nigerian Naira) to travel to the study centre to access ART. In the urban settings, com-
peting activities such as work and social life interfere with time spent queuing in overburdened
health facilities with large patient cohorts. Long waiting time is associated with high attrition
among patients on ART [40]. These challenges can largely be offset by the community-based
ART. In Uganda, a home-based ART delivery model showed similar survival and virological
suppression with a facility-based ART [11]. In Western Kenya, community-based care pro-
vided by PLWHA resulted in similar clinical outcomes as facility care with half the number of
clinic visits [12,13]. In Tanzania, a model of ART delivery by community-based volunteers
linked to trained medical staffs led to fewer patients being lost to follow-up from treatment
[14]. In Mozambique, a rotation community support approach was applied and more than
90% retention at 4 years was reported [41,42]. In Nigeria, our study has demonstrated the fea-
sibility of sustaining high retention in care and low loss-to-follow–up. Some authors have sug-
gested that the community based ART is the key for lifelong ART for the 20 million people in
sub-Sahara Africa [6]. But opponents of the community based interventions argue that once
patients stop coming to the hospital to see the physicians, clinical care and its accrued benefits
will depreciate leading to poor retention in care and loss-to-follow-up. This argument has
however been disproved by several studies that demonstrated comparable clinical and viro-
logic benefits between facility based and home-based treatments [12,14]. This pilot survey has
provided additional evidence in support of the community based ART approach. With task
shifting of HIV care for stabilized patient to CPs and increased uptake of ART services, the
spread of HIV can be minimized with sustained viral suppression and contributing to fast
tracking the UNAIDS 90:90:90 strategy.
Conclusion
Use of community pharmacies for HIV treatment maintenance is feasible in Nigeria with
potential signs of good retention in care. Community pharmacies have a role to play in provid-
ing community ART services and reducing burden on patients and health care providers. Lon-
gitudinal studies (cohort and quasi-experimental) are however needed to provide evidence of
cost-effectiveness to inform future large scale implementation.
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